All posts by admin

British Heart Foundation researchers develop blood test for heart disease

By Jag Buttoo, Director of Business Development at Creavo Medical Technologies

Yesterday’s news that researchers have developed a high-sensitivity blood test that measures the level of troponin in a person’s system to predict which patients are most at risk of suffering a heart attack is exciting for the prediction and possible prevention of coronary heart disease.

Troponin, which is a protein released into the blood stream when the heart muscle is damaged, is currently used as a cardiac marker in emergency departments to indicate to a clinician whether or not someone has an acute cardiac condition. While this latest research needs to be repeated in a larger and more controlled study, it shows the advances in troponin testing. It could be a major step forward in screening and prediction of coronary heart disease and work alongside more established ways of measuring risk, such as blood pressure and cholesterol levels. This new research appears to indicate that troponin could help doctors to help identify individuals who have silent heart disease, target treatment and then measure which patients are responding to treatment, if it works alongside the more traditional risk factors of smoking, high cholesterol or hypertension.

One issue that doesn’t seem to have been addressed yet is the complexity associated with those patients who have a residual level of troponin in their system. Indeed, this is a challenge that is still playing out with the use of high-sensitivity troponin testing in the detection and diagnosis of acute cardiac events in emergency departments. High-sensitivity troponin tests can identify trace amounts of the protein that may naturally occur in a person’s body which essentially makes them more sensitive but less specific as it could indicate that more people have a cardiac condition. From a clinicians’ point of view, this gives an increasing number of false positives and they have no choice but to send a patient for further testing, potentially resulting in longer hospital stays, unnecessary tests and placing greater strain on already overstretched healthcare systems.

VitalScan, however, ‘rules out’ cardiac-related problems and enables non-cardiac patients to be identified quickly. Where a problem is identified by VitalScan, patients can then go on to be tested using ‘rule in’ tests, such as troponin to determine the specific problem and subsequent treatment. VitalScan is potentially a key tool that will work alongside other tests to ensure that heart problems are detected and diagnosed as quickly and accurately as possible in acute medical settings.

Advances in troponin testing, be it this latest one which focuses on screening and prevention or further research into how high sensitivity troponin tests can better work in emergency departments, is positive, but it should be looked at in context and as part of a number of tests that are at a clinician’s disposal.

Click here to read article from the British Heart Foundation

Creavo featured in new ITN production

Creavo Medical Technologies, an emerging British company developing diagnostics technology for acute medical settings, has been chosen to be featured in a new current affairs-style programme devoted to exploring change and transformation within the NHS.

 

The production, which is called ‘Healthy Communities, Healthy People’, is a joint venture between ITN Productions and the New NHS Alliance. It was launched at the New NHS Alliance Action Summit on 1st December 2016 at The King’s Fund in London and is introduced by national newsreader Natasha Kaplinsky. It features key industry interviews and news-style reports along with sponsored editorial profiles.

 

CEO of Creavo Medical Technologies, Steve Parker, said: “We were delighted to be approached by ITN Productions to be involved in this programme and to talk about the ground-breaking technology we’re developing for improving the triage process for patients entering A&E departments with chest pain. Innovation is vital in the NHS and there needs to be a commitment to technology, research and development if we are to secure its future.”

 

ENDS

Notes to editors

 

About Creavo Medical Technologies Ltd

Creavo Medical Technologies Ltd is a UK-based, privately held medical device company that is developing innovative diagnostic techniques. The company was formed in 2014 to bring to market ground-breaking technology developed by Professor Ben Varcoe, Chair of Quantum Information Science at Leeds University. It has facilities in Leeds and Coventry, UK.

 

Focused on improving front line patient care in acute medical settings, Creavo’s first application of this technology is the VitalScan – a device that meets an urgent clinical need in global cardiology to more accurately ‘rule out’ heart-related problems at point of admission to emergency departments.

 

VitalScan is a battery-powered, portable medical device that uses advanced quantum principles to measure, display and store electromagnetic fluctuations caused by heart activity. Early indications from smaller sets of clinical trials indicate that the device can accurately and quickly rule out significant ischaemic heart disease with near 100% accuracy through a simple, non-invasive three to five-minute scan at a patient’s bedside.

 

For more information about Creavo, please visit: http://www.creavomedtech.com/

 

For further information, please contact:

Annabel John, Speed Communications

07771 916881

Annabel.john@speedcomms.com

 

Leander Clarke, Speed Communications

07985 238713

Leander.clarke@speedcomms.com

 

About the NHS Alliance

New NHS Alliance is a value-led movement of people and organisations who are committed to building a sustainable, community-based health service. It is expanding beyond its core roots in general practice and primary care to embrace people and organisations that can make a positive difference to people’s health and wellbeing. It is focused on heath inequalities and the practice of health creation. It wants to see primary care establish strong connections and collaborations with organisations that make a positive difference to people’s health and wellbeing and become a strong enabler of people-led health improvement. For more information, visit: www.nhsalliance.org

 

About ITN Productions

ITN Productions is ITN’s bespoke production hub producing creative and commercially valuable content for the corporate, commercial, broadcast and digital sectors. Industry News forms part of this offering and is a communications tool for leading industry bodies and national associations produced in a broadcast news programme format, including interviews, news-style items and sponsored editorial profiles. For more information, visit www.itnproductions.co.uk

 

Creavo’s VitalScan receives CE mark

Creavo Medical Technologies, an emerging British company developing diagnostics technology for acute medical settings, is today Wednesday 23 November pleased to announce that its first device, VitalScan, has received CE mark registration, enabling market launch in Europe.

The successful receipt of the CE mark means that the device will now start a largescale, multi-centre clinical trial at four of the UK’s major A&E departments, namely Bristol, Sheffield, – Leicester and Nottingham, followed by a second stage starting at three centres in the United States at Mayo Clinic Rochester, Cincinnati and Baylor Texas.

Early indications from smaller sets of clinical trials indicate that VitalScan could meet an urgent clinical need for improving the current triage process for patients entering emergency departments with chest pain. The device uses advanced quantum principles to measure, display and store electromagnetic fluctuations caused by heart activity through a simple, non-invasive three to five-minute scan at a patient’s bedside. This scan accurately and quickly rules out significant ischaemic heart disease, such as heart attacks. The device will enable clinical practitioners, who operate in acute medical settings, to ‘rule out’ heart-related problems and prevent healthy patients from having to go through the current lengthy, and costly, chest pain triage process, which includes a variety of diagnostic tests including multiple ECGs and cardiac biomarker blood tests.

Dr Richard Charles, Emeritus Consultant Cardiologist at Liverpool Heart and Chest Hospital and Chair of Creavo Medical Technologies’ Medical Advisory Board, said: “There is compelling early evidence that Magnetocardiography (MCG) as utilised in VitalScan, can quickly and accurately rule out suspected heart attack in emergency chest pain patients, rapidly relieving both patient anxiety and health care costs. The development of VitalScan opens an exciting new chapter in understanding and managing heart disease.”

Steve Parker, CEO of Creavo, said: “Receiving the CE mark for VitalScan means that we have achieved one of our critical strategic ambitions for 2016.

“At a time when the NHS is facing unprecedented pressures, VitalScan has the potential to radically disrupt the current process for patients entering emergency departments with chest pain, bringing millions of pounds of savings to the NHS a week, easing pressure on bed space in A&E and reducing patient anxiety. The CE mark means that we can now look forward to building momentum with the launch of our multi-centre clinical study, testing the device in four of the busiest A&E departments in the UK and in the US.”

 

For further information, please contact:
Annabel John, Speed Communications

07771 916881
Annabel.john@speedcomms.com

Leander Clarke, Speed Communications
07985 238713
Leander.clarke@speedcomms.com

 

Notes to editors

About Creavo Medical Technologies Ltd
Creavo Medical Technologies Ltd is a UK-based, privately held medical device company that is developing innovative diagnostic techniques. The company was formed in 2014 to bring to market ground-breaking technology developed by Professor Ben Varcoe, Chair of Quantum Information Science at Leeds University. It has facilities in Leeds and Coventry, UK.

Focused on improving front line patient care in acute medical settings, Creavo’s first application of this technology is the VitalScan – a device that meets an urgent clinical need in global cardiology to more accurately ‘rule out’ heart-related problems at point of admission to emergency departments.

VitalScan is a battery-powered, portable medical device that uses advanced quantum principles to measure, display and store electromagnetic fluctuations caused by heart activity. Early indications from smaller sets of clinical trials indicate that the device can accurately and quickly rule out significant ischaemic heart disease with near 100% accuracy through a simple, non-invasive three to five-minute scan at a patient’s bedside.

For more information about Creavo, please visit: http://www.creavomedtech.com/

Creavo CEO named in The Manufacturer’s Top 100

Steve Parker, CEO of Creavo Medical Technologies Ltd, has been named as one of the UK’s 100 most inspiring individuals as part of The Manufacturer’s Top 100 2016.

With judging criteria spanning from ‘Unsung Hero’ to ‘Young Pioneer’, Steve, who has held senior roles in international medical device companies for the last 35 years, was nominated in the Bold Investor in New Markets category. This was for the instrumental role he has played in the commercialisation of Creavo Medical Technologies’ first device, VitalScan which is about to begin largescale, multi-centre clinical trials. Individuals are nominated for the Top 100 by readers of The Manufacturer, the wider industrial community and the public, for their contributions in changing the face of industry.

Steve, along with 300 others, gathered at an event earlier this week at the Birmingham Museum and Art Gallery to celebrate the Top 100’s launch.

Nigel Fine, Chief Executive of the Institution of Engineering and Technology (IET) and TM Top 100 Judge 2016, said: “The UK’s manufacturing industry makes a significant contribution to the UK economy – so it’s vital that government, employers and professional bodies continue to work together to ensure that our manufacturing industry thrives. The Manufacturer Top 100 is a great way to celebrate the diversity, creativity and success of our manufacturers and inspire role models to attract more young people into manufacturing.”

Steve Parker, CEO of Creavo Medical Technologies, said: “It is a huge honour to be recognised with so many leaders in the manufacturing industry. This is not only the result of my own hard work, but that of the whole team at Creavo to get us in a position to launch the clinical trials of our first device within just two years of the company’s establishment as a spin-out from the University of Leeds.”

www.themanufacturertop100.com

For Further Information:-
Steve Parker (CEO) Creavo Medical Technologies
07743 895261 or 01926 670560
steve.parker@creavomedtech.com
www.creavomedtech.com

Annabel John, Speed Communications
07771 916881
annabel.john@speedcomms.com

A look back at this year’s NHS Health and Care Innovation Expo

A look back at this year’s NHS Health and Care Innovation Expo

This year’s Health and Care Innovation Expo in Manchester was once again well-attended with an impressive speaker list which included Secretary of State for Health, Jeremy Hunt, Chief Executive of NHS England, Simon Stevens and NHS England Medical Director, Sir Bruce Keogh addressing the audience.

One of the key areas of focus was the evolution and expansion of the vanguard programme, which was established during 2015 to improve the coordination between urgent and emergency care services to ease pressure on accident and emergency services within the NHS and to develop new care models to act as best practice blueprints for the NHS in the future.

This focus on bridging the gap between community and emergency departments is one seen in many countries around the world to try and get the right care to the right people. It is also designed to ensure that patients do not embark on costly treatment paths inappropriately adding costs and potentially delaying appropriate treatment.

During the course of the exhibition, a number of representatives from vanguards visited our booth where we showcased our VitalScan device. We explained how an early “rule out” model could be used to better diagnose patients with chest pain before they enter the accident and emergency care path. While the current GP model would immediately refer any patients experiencing chest pain to A&E departments, the new vanguard model will see GPs taking on some of the initial triage process. Accurate and reliable rule out tests will be key to this success. In addition, there was a lot of discussion about how VitalScan and the Cardiac Tool Kit could be used to monitor high risk cardiac patients over time.

The 2016 NHS Innovation Expo highlighted that there is a real appetite for change and innovation within the NHS; change that can deliver process improvement, cost savings and patient outcome benefits is the focus of a number of initiatives and programmes. This appetite is seen across the full UK health sector, National Institute for Health Research, Department of Health, NHS England and the Academic Health Science Networks. We look forward to continuing to engage positively with representatives from all of these organisations to help deliver improvements to services that will ultimately enable patients to access the care and treatment they need more quickly.

Name change aligns company to greater global ambition

Quantum Imaging is pleased to announce that it is changing its name to Creavo Medical Technologies Ltd (Creavo) in a move to better align its brand identity with its ambition as an innovative developer of medical technology for a range of global healthcare markets. The name change will take immediate effect.

Quantum Imaging has enjoyed a successful first six months of 2016. It has met many commercial milestones, including receiving ISO certification from the British Standards Institute, and award recognition in the fields of innovation and leadership.

The company has also grown significantly with recruitment across a range of specialist disciplines, including clinical and research. Such success has inevitably seen the company’s vision and values evolve to fully exploit the global opportunities for its ground-breaking diagnostic and detection technology. The name change reflects this wider thinking and provides room for further growth and development as the company moves closer to their commercialisation of its first piece of technology.

CEO of Creavo, Steve Parker said: “The first half of 2016 has been very positive for us andwe have achieved everything we set out to do to ensure that our technology becomes a reality. We are a forward-looking company and therefore wanted a brand identity that elevated us beyond the principles of quantum technology and reflected the real innovation and opportunity our finished products will deliver to global healthcare markets. We believe Creavo gives us this and we are excited to be moving in this direction.”

Creavo’s first product, VitalScan is set to receive a CE mark for European sale this autumn. This will be followed by a multi-centre clinical trial of up to 1,000 patients beginning before the end of 2016.

A look back at this year’s European Society of Cardiology Congress

Steve Parker, CEO of Quantum Imaging, looks back at this year’s highlights from the annual European Society of Cardiology Congress

The hot and crowded summer streets of Rome have been swelled this week as 30,000 attendees gathered for the world’s largest annual cardiology event, The European Society of Cardiology Congress. As always, a huge amount of material was presented at the event covering all aspects of research and clinical cardiology.

From our perspective, I picked up on several trends and heard interesting presentations that will influence how Acute Coronary Syndromes (heart attack and serious unstable angina) are diagnosed and the potential positive impact that those trends may have on the acute use of Magnetocardiography.

As more and more sensitive troponin assays (hscTn) are used, the debate continues about exactly how they should be deployed – and in the US there is debate over whether they should be used in clinical practice at all. One session at the Congress explored the use of hscTn and confirmed that there is little debate over what should happen to patients who present at emergency departments with “classic chest pain” and grossly elevated levels of high sensitive troponin. The majority of patients, however, will have a “slightly elevated” level of troponin which may, or may not, be diagnostic and will require further testing and serial blood tests. This moves from what was a “black and white” decision about raised troponins to one where troponin is only one factor in a much broader evaluation of the patient, including comorbidities, age etc.

In the United States, which represents an estimated third of the world’s potential market, the use of hscTn is yet to have been approved by the FDA because their concerns over it are yet to be adequately addressed. This debate stems back to 2012 when a document was issued raising concerns about how patients in the “grey zone” should be treated and how the false positives associated with higher-sensitivity troponin testing should be readily and safely identified. To date, there has still not been an answer that has satisfied the FDA to the extent where it has approved the use of high sensitive troponin assays.

Another interesting presentation was the findings of a group at the University of Leeds lead by the Professor of Cardiovascular Health Sciences, Dr Chris Gale. Dr Gale’s findings were extensively reported in the UK media with headlines such as the BBC’s “Third ‘given wrong initial heart attack diagnosis’” and The Times’ “Doctors miss signs of heart attack in women”. Data from 600,000 patients over 9 years was reviewed and it was found that 35% of women who were initially told that they were suffering from something other than what ultimately turned out to be a heart attack.

In response, a spokeswoman for NHS England commented: “We are working hard to continually improve tests for accurately diagnosing heart attacks in both men and women so that treatment can begin without delay…” This once again underpins the clear, and urgent, need for accurate and deployable testing for chest pain patients in acute areas of the hospital.

In summary, the high sensitivity discussion continues, but with each round there is a growing call for deployable technology that can sit alongside high-sensitive troponin tests to better manage patients who test positively and negatively to ensure that they end up on the correct diagnostic pathway, without adding significant institutional costs further down the line. Today, much of this is starting to be picked up by expensive imaging elsewhere in the hospital and in many cases during expensive and invasive cath lab procedures. All this essentially amounts to a growing evidence bank which indicates that deploying hscTn in the emergency room increases costs for already stretched healthcare budgets.

New appointment helps local company go global

New appointment helps local company go global

Coventry-based Quantum Imaging Ltd, has appointed a business development director to develop its overseas distribution network and enable the company to grow globally.

Jag Buttoo joined the award winning company from GE Healthcare, where he held a number of senior sales positions in the UK, Ireland and the Middle East. He has more than 23 years’ experience in the medical industry, including five years of clinical experience as a qualified radiographer and 18 years in a commercial role working in a range of disciplines, such as cardiology.

In his role at Quantum Imaging, Mr Buttoo will establish the business’ overseas distribution network, focusing on Europe and the Middle East initially. He will also be responsible for the direct sales market in the UK and USA, looking to develop strong sales and marketing networks for the company’s first product, VitalScan.

VitalScan is set to revolutionise the detection of heart-related problems in acute medical settings. It is a portable medical device that can scan a patient with chest pain in less than five minutes, helping doctors to ‘rule out’ cardiac conditions, such as heart attacks. VitalScan can be used in hospital accident and emergency departments or by a patient’s bedside placing it at the front-line of medical care.

Mr Buttoo said: “I have been looking for a role within an emerging technology company for some time and Quantum Imaging felt like a perfect fit. Its technology is going to be a game-changer for cardiology and helping to build the sales network from the ground up is a huge privilege. The company’s values and vision reflect my own and I am very excited to be part of such a forward-looking organisation.”

Mr Buttoo’s is the latest in a series of appointments at the organisation, spanning researchers and clinical managers, to business development specialists and technical engineers.

CEO of Quantum Imaging, Steve Parker, said: “With VitalScan being taken forward for clinical trials later this year we are getting ever closer to commercialisation. We therefore need to be looking towards reaching out to global markets with this technology, maximising its potential to change lives for patients globally. Jag has the right mix of experience and enthusiasm to make this happen and we are very pleased to have him as part of the team.”

For further information, please contact:
Annabel John, Speed Communications
07771 916881
Annabel.john@speedcomms.com

Leander Clarke, Speed Communications
07985 238713
Leander.clarke@speedcomms.com

CEO Award winner Steve Parker thanks team for success

Steve Parker, CEO of Coventry-based Quantum Imaging Ltd has been recognised in this year’s CEO of the year awards by Finance Monthly magazine but says success is thanks to the hard-work and innovation of his whole team.

The award celebrates Steve and his team’s dedication to bringing ground-breaking technology to market that will help emergency room staff rule out heart attacks and other serious heart problems.

Every year Finance Monthly celebrates the success, innovation and strategic vision of CEOs across a wide variety of sectors and industries globally.

Finance Monthly’s Editor-in-chief, Mark Palmer commented: “It is vital for every business striving for success to have a leader whose diligence, innovative thinking and ingenuity inspire their team to demonstrate the same qualities and achieve excellence. We are happy that all of the individuals listed within Finance Monthly’s 2016 CEO Awards are corporate leaders who aspire to these qualities and whose enthusiasm and hard work help their companies successfully accomplish their goals.”

With Steve at the helm, Quantum Imaging has moved forward rapidly since its formation in 2014, achieving several key milestones. He was the driving force behind securing two successful rounds of investment which have been essential in bringing this innovative technology to life. Earlier this year, the company received an ISO13485 certification from the British Standards Institute (BSI) in recognition of its quality management systems, ensuring it operates with consistent, high-quality internal practices and customer support.The company, which moved to Coventry earlier this year has substantial growth plans in 2016/17 and further accreditations are expected.

Steve has built an experienced management team which includes specialists from a range of disciplines, including fundamental and clinical research, medical technology commercialisation, manufacturing and global regulatory and clinical strategy to ensure further successful growth.

Steve Parker says: “This award belongs to everyone at Quantum Imaging. I am surrounded by the best in the industry and that makes my job that much easier. Winning this award cements the company’s achievements to date and is well deserved for all the hard work, creative thinking and leadership demonstrated by the entire team. I would like to thank everyone that has supported me and we can all look forward with excitement. The global opportunity for our products is massive and we are in a good position to make this a reality.”

Quantum Imaging is bringing its first product, Quantum VitalScan, forward for clinical trials later this year with a multicentre international clinical study.